Current reports

13/2022 KDPW’s statement on the assimilation of S series ordinary bearer shares of the Company
12/2022 Admission and introduction of S series ordinary bearer shares of the Company to stock exchange trading
11/2022 Registration of the Company as the manufacturer of the SARS-CoV-2 rS active substance in the Register of the Chief Pharmaceutical Inspectorate
10/2022 Conclusion of an annex to the agreement on co-financing of the project entitled “Expansion of the Research and Development Centre of Mabion S.A. – research on the new generation of medicines”
09/2022 Change of the publication date of the annual report for 2021
08/2022 Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities
07/2022 Decision to abandon further implementation of the research project on the development of MabionEGFR
06/2022 Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities.
05/2022 Allotment of shares and increase of the Company’s share capital as part of a conditional share capital increase
04/2022 Announcement of the National Depository of Securities (Krajowy Depozyt Papierów Wartościowych S.A.) concerning the registration of S series shares of the Company.
03/2022 Mabion receives an additional order to provide analytical product quality control services under manufacturing agreement with Novavax, Inc.
02/2022 Mabion receives an additional order for the production of cellular banks under the manufacturing agreement with Novavax, Inc.
01/2022 Deadlines for publication of periodic reports in the financial year 2022.
70/2021 Notification of transactionson Mabion S.A.’s shares performed by a person discharging managerial responsibilities.
69/2021 Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with reumatoid arthritis in Ukraine.
68/2021 Subscription summary for the Company’s S series ordinary bearer shares as part of the Incentive Scheme for 2020.
67/2021 An addendum to Current Report no. 26/2021 containing information on the completed subscription of U series shares issued by Mabion S.A.
66/2021 Mabion executes an annex to the borrowing agreement with Glatton Sp. z o.o.
65/2021 Resignation of a member of the Company’s Supervisory Board.
64/2021 Mabion enters into an agreement for the supply of four bioreactors to the Company’s manufacturing facility.
63/2021 Mabion enters into a quality agreement as part of its collaboration with Novavax, Inc.
62/2021 Termination of the cooperation agreement with Mylan Ireland Ltd.
61/2021 Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.
60/2021 Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.
59/2021 Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.
58/2021 Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.
57/2021 Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with rheumatoid arthritis in Belgium.
56/2021 Change of the publication date of the Q3 2021 report.
55/2021 Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.
54/2021 Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with rheumatoid arthritis in Georgia.
53/2021 Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with rheumatoid arthritis in Poland.
52/2021 Information on the execution of a commercial manufacturing agreement with Novavax, Inc. for the period of 2022-2025
51/2021 Registration of amendments to the Company’s Articles of Association.
50/2021 Change of the permit for business activity in the Łódź Special Economic Zone.
49/2021 Adoption of a joint work programme for the marketing authorisation of MabionCD20 in the European and US markets and elaboration of the final data and clinical trial scope for the registration application on the European market.
48/2021 Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities.
47/2021 Receipt of the notice of the company’s shareholding
46/2021 Notification of transactions on Mabion S.A. shares performed by the person discharging managerial resposibilities.
45/2021 Update on the cooperation with Novavax Inc. on the COVID-19 vaccine programme.
44/2021 List of shareholders holding at least 5% of votes at the Ordinary General Meeting of the Company on June 22, 2021
43/2021 Appointment of a Member of the Company’s Supervisory Board. Appointment of a Member of the Company’s Supervisory Board
42/2021 The content of the resolutions of the Ordinary General Meeting of Mabion S.A. of 22 June 2021
41/2021 Receipt of the notice of change in the company’s shareholding.
40/2021 Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities.
39/2021 Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities.
38/2021 Receipt of a motion to supplement the agenda of the General Meeting and a candidacy for Member of the Supervisory Board
37/2021 Announcement on convening the Ordinary General Meeting of Mabion S.A. on June 22, 2021, alongside with draft resolutions
36/2021/K Changes in the composition of the Company’s Management Board and Supervisory Board – correction of the numbering of the Current Report of 13 May 2021.
36/2021 Changes in the composition of the Company’s Management Board and Supervisory Board.
35/2021 Conclusion of an annex to the cooperation agreement with Mylan Ireland Ltd.
34/2021 Admission and introduction of ordinary bearer series U shares of the Company to stock exchange trading
33/2021 The conditional registration of series U shares of the Company with the National Depository for Securities
32/2021 Change of the publication date of the annual report for 2020
31/2021 Registration of the share capital increase and amendments to the Articles of Association
30/2021 Information on the performance of the first order under a framework agreement with Novavax, Inc.
29/2021 Registration of rights to series U shares of the Company in KDPW
28/2021 Admission and introduction of the rights to ordinary bearerseries U shares of the Company to exchange trading
27/2021 Conditional registration of rights to series U shares of theCompany in KDPW
26/2021 Information regarding the completed subscription for series Ushares issued by Mabion S.A.
25/2021 Cancellation of the Extraordinary General Meeting of MabionS.A. called for 22nd March 2021 and information on the review of the Company’s financing strategy
24/2021 Notifications about transactions on Mabion S.A. shares made by persons closely related to persons discharging managerial responsibilities in the Company
23/2021 Conclusion of contracts for the subscription for series U Mabion S.A. shares
22/2021 Notification of transactions on Mabion S.A. shares performed bythe person discharging managerial responsibilities
21/2021 Determination of the issue price of new Series U shares issued by MabionS.A. and the final number of series U shares to be offered by the Company
20/2021 Information on declarations of particular shareholderssubmitted in connection with the book-building process
19/2021 Mabion S.A. concludes a placement agreement and commences the book-building process for an offering by way of private subscription ofnew Series U ordinary bearer shares issued by Mabion S.A.
18/2021 Changes in the composition of the Management Board and Supervisory Board of the Company
17/2021 Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities
16/2021 Conclusion of a preliminary agreement with Polski Fundusz Rozwoju S.A.
15/2021 Entering into a master service agreement with the first work order with Novavax Inc. for contract services related to the COVID-19 vaccine program
14/2021 List of shareholders holding at least 5% of votes at the Extraordinary General Meeting of the Company on February 23, 2021
13/2021 Changes in the composition of the Supervisory Board of the Company
12/2021 Content of resolutions of the Extraordinary General Meeting of Mabion S.A. of 23 February 2021
11/2021 Announcement on the convening of the Extraordinary General Meeting of Mabion S.A. of March 22, 2021 together with draft resolutions
10/2021 Issue of shares as part of the conditional increase of the Company’s share capital
9/2021 Registration of S series shares in KDPW
8/2021 Admission and introduction of S series shares to exchange trading
7/2021 Resignation of a Member of the Supervisory Board of the Company
6/2021 Receipt of nomination for member of the Supervisory Board of the Company
5/2021 Conclusion of a loan agreement with Twiti Investments Limited
4/2021 Announcement on convening the Extraordinary General Meeting ofMabion S.A. on February 23, 2021, alongside with draft resolutions
3/2021 Decision on commencing activities aimed at attracting astrategic investor for the Company and on two planned issues of the Company’s shares
2/2021 Assignment of Supervisory Board member to perform the duties of a member of the Management Board
1/2021 Dates for submission of periodical reports in the financial year of 2021
48/2020 Statement of the National Depository for Securities S.A. concerning: the conditional registration of series S shares with the National Depository for Securities
47/2020 The fifth summons to shareholders of Mabion S.A. for submitting the share documents in the Company’s registered office
46/2020 Conclusion of an annex to the loan agreement with Glatton Sp. z o.o.
45/2020 Update of information regarding the Company’s cooperation with Vaxine Pty Ltd. regarding a potential Covid-19 vaccine
44/2020 The fourth summons to shareholders of Mabion S.A. forsubmitting the share documents in the Company’s registered office
43/2020 The third summons to shareholders of Mabion S.A. for submitting the share documents in the Company’s registered office
42/2020 Updated information concerning the Company’s cooperation with Vaxine Pty Ltd. in scope of a potential Covid-19 vaccine
41/2020 Conclusion of an agreement with Parexel to conduct the final clinical trial before submitting a marketing authorisation application for MabionCD20 to the European Medicines Agency (EMA)
40/2020 Signing of the initial understanding in scope of cooperation covering research, development, and commercialisation of the antibodies of drug MabionCD20 in specific clinical indications concerning rare diseases.
39/2020 Receipt of a notification of change in the ownership of the Company’s shares
38/2020 The second summons to shareholders of Mabion S.A. for submitting the share documents in the Company’s registered office
37/2020 Signing of a Letter of Intent (LoI) on development work and production of the “IL-1R7 Antibody”, developed as a possible medication to treat Covid-19 infections.
36/2020 The first summons to shareholders of Mabion S.A. for submitting the share documents in the Company’s registered office
35/2020 Assignment of Supervisory Board member to replace a member of the Management Board
34/2020 Conclusion of Memorandum of Understanding on potential cooperation regarding a product that may be a vaccine for Covid-19 disease
33/2020 Resignation of a Member of the Management Board of the Company.
32/2020 Information regarding a meeting with the US Food and Drug Administration (FDA) concerning registration and marketing authorization for MabionCD20 drug on the territory of the USA.
31/2020 Conclusion of loan agreements from the main Shareholders of the Company
30/2020 Conclusion of loan agreement with Glatton Sp. z o. o.
29/2020 Information on initial assumptions regarding the renewed Marketing Authorization Application to be filed for MabionCD20
28/2020 Receipt of a written response from the European Medicines Agency as a part of the ‘Scientific Advice’ regarding the assumptions for the new registration process for MabionCD20
27/2020 Summary of the subscription of S series ordinary bearer shares of the Company carried out under the Incentive Scheme for 2019
26/2020 Satisfaction of the condition of the permit to conduct business activity in the Łódź Special Economic Zone.
25/2020 List of shareholders holding at least 5% of votes at the Ordinary General Meetingof the Company on June 15, 2020.
24/2020 Appointment of Supervisory Board members for the second term
24/2020 Attachment
23/2020 Content of the resolutions of the Ordinary General Meeting of Mabion S.A. of June 15, 2020
22/2020 Announcement on convening the Ordinary General Meeting of Mabion S.A. on June 15, 2020, along with draft resolutions
21/2020 Decision on the intention to issue U series ordinary bearer shares of the Company in order to increasethe share capital of Mabion S.A.
20/2020 Change of publication date of the annual report for 2019
19/2020 Information on the withdrawal of registration applications for MabionCD20 from the EMA
18/2020 Changes in the positions of Chairman and Deputy Chairman of the Supervisory Board
17/2020 Information on the impact of the COVID-19 spread on the Company’s activities
16/2020 Arrangements for financing the Company’s operations in light of the new regulatory strategy for registration of MabionCD20 in the EMA
15/2020 Change of regulatory strategy for the marketing authorisation of MabionCD20 in the EMA
14/2020 Resignation of a Member of the Supervisory Board of the Company and appointment of President of the Management Board of the Company
13/2020 Update on the registration procedure for the marketing authorisation of MabionCD20 by the European Medicines Agency
12/2020 Receipt of a summary of a BPD Type 3 meeting with the Food and Drug Administration (FDA) on the registration and marketing authorisation of MabionCD20 in the USA
11/2020 Receipt of the list of issues to be presented at the meeting of the Committee for Medicinal Products for Human Use to be held on 24-27 February 2020
10/2020 Change of the building permit for Mabion S.A. Science and Technology Centre for Advanced Medical Biotechnology in Konstantynów Łódzki.
9/2020 Change of the authorisation to conduct business activity in the Łódź Special Economic Zone
8/2020 Issue of shares under a conditional increase of the Company’s share capital
7/2020 Submitting answers to the questions as part of the registration procedure for MabionCD20 with the European Medicines Agency
6/2020 Registration of P and S series shares in KDPW
5/2020 Admission and introduction of P and S series shares to exchange trading
4/2020 Information regarding a Type 3 BPD meeting with the Food and Drug Administration (FDA) on the registration and marketing authorisation of MabionCD20 in the USA
3/2020 Declaration of the National Depository for Securities (KDPW) on conditional registration of P and S series shares in the KDPW
2/2020 Update information on the registration procedure for MabionCD20.
1/2020 Dates of publication of periodic reports in the financial year 2020.
38/2019 Receipt of the summary from the CHMP meeting regarding the registration procedure of the MabionCD20 drug.
37/2019 Update of information concerning the registration of drug MabionCD20 for marketing authorisation and disclosure of delayed confidential information.
36/2019 Obtaining approval on extension of the research project deadline from the National Centre for Research and Development.
35/2019 Registration of conditional increase of share capital and amendment to the Articles os Association.
34/2019 List of shareholders holding at least 5% of votes at the Extraordinary General Meeting of the Company on November 29, 2019.
33/2019 Summary of the subscription of the Company’s ordinary series S bearer shares carried out as part of the implementation of the Incentive Program for 2018.
32/2019 Contents of resolutions adopted by the Extraordinary Meeting of Shareholders of Mabion S.A. on 29 November 2019.
31/2019 Notifications about transactions on Mabion S.A. financial instruments made by a person discharging managerial responsibilities.
30/2019 Submission of answers to the Company’s Duplicate application for registration of MabionCD20 with the European Medicines Agency.
29/2019 Responses to round two of inquiries in scope of the registration procedure of MabionCD20 in the European Medicines Agency.
28/2019 Notice of convening the Extraordinary General Meeting of Mabion S.A. to be held on November 29, 2019, with draft resolutions attached.
27/2019 Appointment of BPD Type 3 meeting with the US Food and Drug Administration_FDA_concerning registration and marketing authorisation for the drug MabionCD20 within the territory of the United States.
26/2019 Agreement reached on the terms and conditions of and a decision made to conclude finance documentation with the European Investment Bank.
25/2019 Obtaining the GMP certificate for the Complex in Konstantynow Lodzki in the field of manufacturing a medicinal product.
24/2019 Information on cooperation with Mylan.
23/2019 Registration of amendment to the Company’s Statute.
22/2019 Information from the European Medicines Agency on the assessment of the results of GMP inspection related to MabionCD20 production in the complex in Konstantynów Łódzki.
21/2019 Mabion S.A. obtains the GMP certificate for the complex in Konstantynów Łódzki for the production of the production of the active substance.
20/2019 Receipt of the second round of questions in the MabionCD20 registration procedure at the European Medicines Agency.
19/2019 Update of information on the composition of the Management Board of the Company.
18/2019/K List of shareholders holding at least 5% of votes at the Ordinary General Meeting of the Company on June 18, 2019. – correction
18/2019 List of shareholders holding at least 5% of votes at the Ordinary General Meeting of the Company on June 18, 2019.
17/2019 Content of the resolutions of the Ordinary General Meeting of Mabion S.A. of June 18, 2019.
16/2019 Implementation of the last condition of permission for conducting the operation in the Lodz Special Economic Zone at the Scientific and Industrial Complex of Medical Biotechnology in Konstantynow Lodzki.
15/2019 The acceptance of the second registration application for MabionCD20 drug for assessment by the European Medicines Agency.
14/2019 Notice of convening the Ordinary General Meeting of Mabion S.A. to be held on June 18, 2019, with draft resolutions attached.
13/2019 The submission of the second registration application concerning MabionCD20 drug to the European Medicines Agency.
12/2019 Receipt of the notice of a change in ownership of the Company’s shares
11/2019 Resignation from the function of President of the Company’s Management Board.
10/2019/K Submission of answers as part of the registration procedure for MabionCD20 at the European Medicines Agency – report correction.
10/2019 Submission of answers as part of the registration procedure for MabionCD20 at the European Medicines Agency.
9/2019 Change in the date of publication of the annual report for 2018.
8/2019 The update on development strategy of medicinal products.
7/2019 Conversion of ordinary registered series P shares into ordinary bearer shares.
6/2019 Information on the registration procedure for MabionCD20 in Turkey.
5/2019 Fulfilment of the condition stipulated in the permit for conducting economic activity in the area of the Lodz Special Economic Zone at the Medical and Biotechnology Complex in Konstantynow Lodzki.
4/2019 Notification about transactions on Mabion S.A. shares made by a person closely associated with a person fulfilling managing responsibilities
3/2019 Notification about transactions on Mabion S.A. shares made by a person closely associated with a person fulfilling managing responsibilities
2/2019 Dates of publication of periodic reports in the financial year 2019.
1/2019 Notifications about transactions on Mabion S.A. performed by person fulfilling managing responsibilities.
63/2018 Change in the Company’s Management Board.
62/2018 Notifications about transactions on Mabion S.A.
61/2018 Filing an application for an extension of patent protection in PCT procedure as part of the MabionMS project.
60/2018 Receiving a building permit for ”The Scientific and Technological Center of Advanced Medical Biotechnology Mabion S.A” in Konstantynów Łódzki.
59/2018 Submission of the second patent application under the MabionMS project.
58/2018 Receipt of payments for the implementation of the key stage of the cooperation agreement with Mylan Ireland.
57/2018 Receipt of the notification of the change in the number of Company’s shares.
56/2018 Granting of approval from The European Medicines Agency for submitting the second registration application (‘Duplicate application) for the drug under the working name MabionCD20.
55/2018 Signing a revolving credit agreement with BZ WBK S.A.
54/2018 Ordinary General Meeting of Shareholders on 28th June 2018 – list of shareholders with at least 5% of the votes.
53/2018 Appointment of Members of the Supervisory Board.
52/2018 The content of the resolution of the Ordinary General Meeting of Shareholders of Mabion S.A. on 28th June 2018.
51/2018 Resignation of the Member of the Supervisory Board of the Company.
50/2018 Information regarding a meeting with the US Food and Drug Administration _FDA_ concerning registration and marketing authorization for MabionCD20 drug on the territory of the USA.
49/2018 Resignation of the Member of the Supervisory Board of the Company.
48/2018 Announcement of candidacy for the Member of the Supervisory Board of the Company.
47/2018 Resignation of the Chairman of the Supervisory Board of the Company.
46/2018 Acceptance for evaluation of marketing authorization application for MabionCD20 drug by the European Medicines Agency.
45/2018 The submission by the shareholder drafts of resolutions for the Ordinary General Meeting of Mabion S.A. convened on 28th
44/2018 Announcement of candidacy for the Member of the Supervisory Board of the Company.
43/2018 Registration of class P shares in KDWP.
42/2018 Signing the grant agreement on the project of the building extension of the Research and Development Center of Mabion S.A.
41/2018 Admission and introduction of P class shares to stock exchange trading.
40/2018 Announcement of candidacy for the independent Member of the Supervisory Board of the Company.
39/2018 Statement of Krajowy Depozyt Papierów Wartościowych S.A. on conditional registration of shares.
38/2018 The Reports of Mabion S.A. Management Board submitted to Ordinary General Meeting convened on 28th June, 2018.
37/2018 The announcement on summoning the Ordinary General Meeting of Mabion S.A. on 28th June, 2018, along with draft resolutions.
36/2018 The application for approval of MabionCD20 to the European Medicines Agency.
35/2018 Confirmation of the final results of the Mabion CD20 NHL clinical trial.
34/2018 The change of ordinary series P bearer shares into ordinary nominative shares.
33/2018 Receipt of the notification of the change in the number of Company’s shares.
32/2018 Change of publication date of the report for the first quarter of 2018.
31/2018 Receipt of the notification of the change in the number of Company’s shares.
30/2018 Receipt of the notification of the change in the number of Company’s shares.
29/2018 Receipt of the notification of the change in the number of Company’s shares.
28/2018/K The registration of the share capital increase through the issue of series P shares and repealing the records of the Statute concerning the authorized capital-adjustment.
28/2018 The registration of the share capital increase through the issue of series P shares and repealing the records of the statute concerning the authorized capital.
27/2018 Notification of transactions on Mabion S.A. shares done by a person closely related to a peson discharging managerial responsibilites.
26/2018 Execution of the argeement on subscription of P shares with Twiti Investements Ltd.
25/2018 List of shareholders holding at least 5% of votes at the Extraordinary General Meeting of the Company.
24/2018 Changes of the Articles of Association of Mabion S.A. by the Extraordinary General Meeting on 18 April 2018.
23/2018 Resolutions adopted by the Extraordinary General Meeting of the Company on 18 April 2018.
22/2018 Expansion of Mabion S.A.’s Research and Development Centre selected for co-funding.
21/2018 Receipt of notification of a change in the status of ownership of the Company’s shares.
20/2018 Receipt of the notification of the status of ownership of the Company’s shares.
19/2018 Receipt of notification of a change in the status of ownership of the Company’s shares.
18/2018 Change of the publication date of the annual report for 2017.
17/2018 Notification of transactions in shares of Mabion S.A. Carried out by a person discharging managerial responsibilities.
16/2018 Planned amendments to the Company’s Articles of Association.
15/2018 Convocation of the Extraordinary General Meeting of Mabion S.A. for 18 April 2018 with draft resolutions.
14/2018 Execution of agreements related to funding obtained by Mabion S.A. (correction).
13/2018 Confirmation of the final results of the Mabion CD20 RZS clinical trial.
12/2018 Execution of agreements related to funding obtained by Mabion S.A.
11/2018 Registration of N and O shares in the Central Securities Depository.
10/2018 Admission and introduction of N and O shares to stock exchange trading.
9/2018 Conditional registration of N and O shares in the Central Securities Despository.
8/2018 Notification of transactions in shares of Mabion S.A. carried out by a person discharging managerial responsibilities.
7/2018 Notification of transactions in shares of Mabion S.A. carried out by a person discharging managerial responsiblities.
6/2018 Results of the clinical trial related to MabionCD20 NHL in relation to other pharmacokinetic endpoints.
5/2018 Notification of transactions in shares of Mabion S.A. carried out by a person discharging managerial responsibilities.
4/2018 Information on the last visit of the last patient in the MabionCD20 NHL trial and conclusion of long-term observation.
3/2018 Results of the clinical trial related to MabionCD20 NHL in relation to certain secondary phamacokinetic endpoints (treatment efficacy and general safety profile).
2/2018 Positive initial results of the clinial trial related to Mabion CD20 NHL in reletion to the primary pharmacokinetic secondary endpoints.
1/2018 Dates of publication of interim reports in the financial year 2018.